University of Groningen

Tumor immunology in ovarian cancer

Merkus-Brunekreeft, Kim

DOI:
[10.33612/diss.147014180](https://doi.org/10.33612/diss.147014180)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Merkus-Brunekreeft, K. (2020). *Tumor immunology in ovarian cancer*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.147014180>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Kim L. Brunekreeft

TUMOR
IMMUNOLOGY
IN OVARIAN
CANCER

COLOPHON

Kim Liu-Yun Brunekreeft

PhD dissertation, University of Groningen, The Netherlands

Layout: Floris Sprong

Cover design: ninamaakt.nl

Photography: Dirk Jansen

Printing: Gildeprint - www.gildeprint.nl

Copyright © 2020 by Kim Liu-Yun Brunekreeft. All rights reserved. Any unauthorized reprint or use of this material is prohibited. No part of this thesis may be reproduced, stored or transmitted in any form or by any means without written permission of the author, or, when appropriate, of the publishers of the publications.

The studies in this thesis were performed at the department of Obstetrics and Gynecology of the University Medical Center Groningen (UMCG); the department of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University Clinic of Würzburg, Würzburg, Germany; and the department of Developmental Immunology of the La Jolla Institute for Immunology, La Jolla, CA, USA.

This work was financially supported by the Junior Scientific Masterclass Groningen of the University of Groningen and the department of Obstetrics and Gynecology of the University Medical Center Groningen. The UEF-JSM Talent Grant (2014) and Jan Kornelis de Cock grant (2015) to drs. K.L. Brunekreeft. The Alexander von Humboldt Foundation and Bas Mulder Award to dr. M. de Bruyn (UMCG 2014-6719). Grants from the Netherlands Organization for Scientific Research (NOW) and Dutch Cancer Society (KWF) to prof. dr. E. Bremer.

Printing of this thesis was financially supported by the University of Groningen and the Graduate School of Medical Sciences of the the University Medical Center Groningen.

**rijksuniversiteit
 groningen**

TUMOR IMMUNOLOGY IN OVARIAN CANCER

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 16 december 2020 om 16:15 uur

door

Kim Liu-Yun Brunekreeft

geboren op 25 januari 1990
te Taipei, Taiwan ROC

The digital version of this thesis can be found online at:
<https://www.gildeprint.nl/case/tumor-immunology-in-ovarian-cancer/>
Or by scanning the QR-code.

Promotor

Prof. dr. H.W. Nijman

Copromotor

Dr. M. de Bruyn

Beoordelingscommissie

Prof. dr. W. Helfrich

Prof. dr. S. de Jong

Prof. dr. H. Wajant

Paranimfen

K. Zunderdorp

W. Foppen

Voor mijn moeders

TABLE OF CONTENTS

Chapter 1	General introduction, aim and outline of this thesis	11	Chapter 7	Summary, discussion, conclusion and future perspectives	175
Chapter 2	Deep immune profiling of ovarian tumors, draining lymph nodes and circulating cells during neoadjuvant chemotherapy. <i>Onc Immunology (2020) 9(1):1-12*</i>	23	Chapter 8	Nederlandse samenvatting (Dutch summary)	187
Chapter 3	CD103 ⁺ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ ⁺ CD8αβ ⁺ T cells that can be targeted for cancer immunotherapy. <i>Oncotarget (2016) 15;7(46):75130-75144</i>	63	Appendices	1. Abbreviations	196
Chapter 4	Minimal MHC-I expression after neoadjuvant chemotherapy in ovarian cancer is negatively associated with T-cell-dependent outcome. <i>Onc Immunology (2020) 9(1):1-12*</i>	101		2. List of contributing authors	200
Chapter 5	Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. <i>Molecular Cancer (2014) 13(1):85</i>	119		3. List of publications	203
Chapter 6	Immune-humanized mice carrying patient-derived xenografts as neo-antigen discovery platform for ovarian cancer. <i>Manuscript in preparation</i>	149		4. Dankwoord (acknowledgements)	204
				5. Over de auteur (about the author)	210

**Published as: Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncoimmunology (2020) 9(1):1-12.*